Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FB2001 in Healthy Chinese Subjects
NCT05197179Phase 1Completed
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Compound 7b in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Frontier Biotechnologies Inc. Primary endpoints: Safety and tolerability, Area under the concentration-time curve over the dosing interval (AUC0-τ) and 1 more. Started Dec 2021; status: completed.
02
Drugs
Compound 7b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05197179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197179.